PRIMARY STUDY

β-Caryophyllene, A CB2 Receptor Agonist Produces Multiple Behavioral Changes Relevant To Anxiety And Depression In Mice

Key Findings:  Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety (anti-compulsive-like effect) and depression.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  United Arab Emirates

Year of Pub:  2014


Cannabinoids Studied:  AM-x Synthetic Cannabinoids

Phytocannabinoid Source:  Not Applicable

Terpenes Studied:  ß-Caryophyllene

Receptors Studied:  CB2

DOSING DETAILS   

Study Dosing Objective:  Effective Dose

Established Protocol:  Effective dose

Dosing Regimen:  β-caryophyllene (BCP) 50mg/kg

Starting Dose:  BCP 50mg/kg

Maximum Dose:  BCP 50mg/kg

Additional Notes:  Pharmacodynamic Study Data



Link to study